Mutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus Pneumoniae

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2002 Dec 25

PMID 12499234

Citations 13

Authors

Glen T Hansen

Kelli Metzler

Karl Drlica

Joseph M Blondeau

Affiliations

Soon will be listed here.

Citing Articles

In Vitro Resistance-Predicting Studies and In Vitro Resistance-Related Parameters-A Hit-to-Lead Perspective.

Krajewska J, Tyski S, Laudy A Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204172 PMC: 11357384. DOI: 10.3390/ph17081068.

Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.

Bissantz C, Zampaloni C, David-Pierson P, Dieppois G, Guenther A, Trauner A Antibiotics (Basel). 2024; 13(1).

PMID: 38247631 PMC: 10812724. DOI: 10.3390/antibiotics13010072.

Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the Determination of the Antimicrobial Potency of Compounds.

Krajewska J, Tyski S, Laudy A Antimicrob Agents Chemother. 2023; 67(5):e0137322.

PMID: 37022162 PMC: 10190592. DOI: 10.1128/aac.01373-22.

Drug Combinations to Prevent Antimicrobial Resistance: Various Correlations and Laws, and Their Verifications, Thus Proposing Some Principles and a Preliminary Scheme.

Yi H, Yuan G, Li S, Xu X, Guan Y, Zhang L Antibiotics (Basel). 2022; 11(10).

PMID: 36289938 PMC: 9598766. DOI: 10.3390/antibiotics11101279.

Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Drusano G, Louie A, MacGowan A, Hope W Antimicrob Agents Chemother. 2015; 60(3):1183-93.

PMID: 26711759 PMC: 4775960. DOI: 10.1128/AAC.02177-15.

References

Thomas J, Forrest A, Bhavnani S, Hyatt J, Cheng A, Ballow C . Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42(3):521-7. PMC: 105492. DOI: 10.1128/AAC.42.3.521. View

Craig W . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26(1):1-10; quiz 11-2. DOI: 10.1086/516284. View

Blondeau J, Zhao X, Hansen G, Drlica K . Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001; 45(2):433-8. PMC: 90309. DOI: 10.1128/AAC.45.2.433-438.2001. View

Schentag J, Gilliland K, Paladino J . What have we learned from pharmacokinetic and pharmacodynamic theories?. Clin Infect Dis. 2001; 32 Suppl 1:S39-46. DOI: 10.1086/319375. View

Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K . Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis. 2001; 184(6):794-8. DOI: 10.1086/323086. View

Schmitz F, Boos M, Mayer S, Hafner D, Jagusch H, Verhoef J . Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001; 45(9):2666-7. PMC: 90713. DOI: 10.1128/AAC.45.9.2666-2667.2001. View

Zhao X, Drlica K . Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001; 33 Suppl 3:S147-56. DOI: 10.1086/321841. View

Nagai K, Davies T, Dewasse B, Jacobs M, Appelbaum P . Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother. 2001; 48(3):365-74. DOI: 10.1093/jac/48.3.365. View

Ho P, Yung R, Tsang D, Que T, Ho M, Seto W . Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 2001; 48(5):659-65. DOI: 10.1093/jac/48.5.659. View

10.

Nagai K, Appelbaum P, Davies T, Kelly L, Hoellman D, Andrasevic A . Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother. 2002; 46(2):371-7. PMC: 127073. DOI: 10.1128/AAC.46.2.371-377.2002. View

11.

Zhao X, Drlica K . Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis. 2002; 185(4):561-5. DOI: 10.1086/338571. View

12.

Quale J, Landman D, Ravishankar J, Flores C, Bratu S . Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis. 2002; 8(6):594-7. PMC: 2738490. DOI: 10.3201/eid0806.010275. View

13.

Blaser J, Stone B, Groner M, Zinner S . Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987; 31(7):1054-60. PMC: 174871. DOI: 10.1128/AAC.31.7.1054. View

14.

Drusano G, Johnson D, Rosen M, Standiford H . Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-90. PMC: 187696. DOI: 10.1128/AAC.37.3.483. View

15.

Chen D, McGeer A, de Azavedo J, Low D . Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999; 341(4):233-9. DOI: 10.1056/NEJM199907223410403. View